表紙
市場調査レポート

Tradjenta (2型糖尿病治療薬):予測と市場分析

Tradjenta (Type 2 Diabetes) - Forecast and Market Analysis to 2022

発行 GlobalData 商品コード 232349
出版日 ページ情報 英文 47 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
Tradjenta (2型糖尿病治療薬):予測と市場分析 Tradjenta (Type 2 Diabetes) - Forecast and Market Analysis to 2022
出版日: 2013年07月31日 ページ情報: 英文 47 Pages
概要

当レポートでは、2011年に FDAによって承認された 2型糖尿病治療薬、Tradjenta (linagliptin)について調査分析し、2型糖尿病の概要と治療ガイドライン、競合情勢、製品情報、主要国における売上予測などをまとめ、概略以下の構成でお届けいたします。

第1章 目次

第2章 イントロダクション

第3章 疾病の概要

  • 病因・病態生理
    • 病因
    • 病態生理
  • 予後
    • 生活の質(QOL)
  • 症状

第4章 疾病管理

  • 治療概要
    • 診断と紹介
    • 治療ガイドライン

第5章 競合評価

  • 概要
  • 競合企業の戦略的評価

第6章 製品プロファイル:Tradjenta (linagliptin)

  • 概要
  • 効能
  • 安全性
  • SWOT分析
  • 予測

第7章 付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDHC222DFR

GlobalData has released its new report, "Tradjenta (Type 2 Diabetes) - Forecast and Market Analysis to 2022". The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Tradjenta (linagliptin) was developed by Boehringer Ingelheim and approved by the FDA in 2011. It is being marketed by Boehringer Ingelheim and Eli Lilly.

Scope

  • Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Tradjenta including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Tradjenta for the top ten countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Tradjenta performance
  • Obtain sales forecast for Tradjenta from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
    • 3.1.3. Prognosis
    • 3.1.4. Quality of Life
  • 3.2. Symptoms

4. Disease Management

  • 4.1. Treatment Overview
    • 4.1.1. Diagnosis and Referrals
    • 4.1.2. Treatment Guidelines

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment

6. Tradjenta (linagliptin)

  • 6.1. Overview
  • 6.2. Efficacy
  • 6.3. Safety
  • 6.4. SWOT Analysis
  • 6.5. Forecast

7. Appendix

  • 7.1. Bibliography
  • 7.2. Abbreviations
  • 7.3. Methodology
  • 7.4. Forecasting Methodology
    • 7.4.1. Diagnosed Type 2 Patients
    • 7.4.2. Percent Drug-Treated Patients
    • 7.4.3. Drugs Included in Each Therapeutic Class
    • 7.4.4. Launch and Patent Expiry Dates
    • 7.4.5. General Pricing Assumptions
    • 7.4.6. Individual Drug Assumptions
    • 7.4.7. Generic Erosion
  • 7.5. Physicians and Specialists Included in this Study
  • 7.6. About the Authors
    • 7.6.1. Analyst II - CVMD
    • 7.6.2. Therapy Director - CVMD and Infectious Disease
    • 7.6.3. Global Head of Healthcare
  • 7.7. About GlobalData
  • 7.8. Disclaimer

List of Tables

  • Table 1: Symptoms of Type 2 Diabetes
  • Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes
  • Table 3: Treatment Guidelines for Type 2 Diabetes
  • Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012
  • Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012
  • Table 6: Product Profile - Tradjenta
  • Table 7: Tradjenta SWOT Analysis, 2012
  • Table 8: Global Sales Forecasts ($m) for Tradjenta and Jentadueto, 2012-2022
  • Table 9: Key Launch Dates
  • Table 10: Key Patent Expiries
  • Table 11: Number of High-Prescribing Physicians Surveyed

List of Figures

  • Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy
Back to Top